Human Adipose-Derived Mesenchymal Stem Cells Promote Liver Regeneration.
Saidi R., Rajeshkumar R., Shariftabrizi A., Zimmerman A., Walter O.
Prospective Study, published in J Invest Surg (2015) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- J Invest Surg (2015)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 26204360
- DOI
- 10.3109/08941939.2015.1006379
- Citations
- 14
Abstract (original English)
Background and aims Liver regeneration (LR) is of crucial importance to patients with acute liver failure, those undergoing live donor liver transplantations or extended liver resections. Effective treatment strategies aimed at accelerating liver regeneration could offer major benefits in these patients. Due to easy accessibility, human adipose-derived mesenchymal stem cells (HADMSC) are an attractive source for regenerative medicine. Herein, we investigated the effect of HADMSC on LR in a murine model. We hypothesized that HADMSC will promote LR. Methods Mice were subjected to CCl4-induced acute liver failure (ALF). Animals in the experimental arm were treated with HADMSC prior to CCl4-induced ALF. Liver injury was evaluated using serum levels of alanine aminotransferase (ALT), serum interleukin-6 (IL-6), and histopathology. Liver samples were stained for a specific marker of regeneration, proliferating cell nuclear antigen (PCNA). Results Histology, serum IL-6, and ALT release revealed that HADMSC treatment attenuated liver injury compared with control animals. In addition, animals treated with HADMSC were observed to have improved survival and increased number of PCNA positive cells on histology when compared with controls. Conclusion HADMSCs represent a potential therapeutic strategy to promote liver regeneration.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.